3-(4-methylpiperazin-1-yl)-N-propylpropan-1-amine | 1042528-95-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-(4-methylpiperazin-1-yl)-N-propylpropan-1-amine
• CAS: 1042528-95-9
• 化学式: C₁₁H₂₅N₃
• 分子量: 199.34
• InChiKey: ADGRWTCKHBKSBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-methylpiperazin-1-yl)-N-propylpropan-1-amine 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三乙胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (2S)-3-(4-chlorophenyl)-2-[(4-methoxy-2,3,6-trimethylphenyl)sulfonylamino]-N-[3-(4-methylpiperazin-1-yl)propyl]-N-propylpropanamide
  参考文献：
  名称：

  The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists

  摘要：

  The discovery of a novel series of 8-azabicyclo[3.2.1] octan-3-yl)-3-(4-chlorophenyl) propanamide antagonists of the vasopressin V-1A receptor is disclosed. Compounds 47 and 48 were found to be high affinity, selective vasopressin V-1A antagonists. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.096

文献信息

• Multicomponent Degradable Cationic Polymers
  申请人：Green Jordan J.

  公开号：US20120128782A1

  公开（公告）日：2012-05-24

  Degradable polymers were synthesized that self-assemble with DNA to form particles that are effective for gene delivery. Small changes to polymer synthesis conditions, particle formulation conditions, and polymer structure provides significant changes to efficacy in a cell-type dependent manner. Polymers presented here are more effective than commercially available materials, such as LIPOFECTAMINE 2000 ™, FUGENE®, or polyethylenimine (PEI), for gene delivery to cancerous fibroblasts or human primary fibroblasts. The presently disclosed materials may be useful for cancer therapeutics and regenerative medicine.
• QUINDOLINE COMPOUNDS AND USES THEREOF
  申请人：Arizona Board of Regents on Behalf of the University of Arizona

  公开号：US20220098210A1

  公开（公告）日：2022-03-31

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quindoline (or similar) structure which function as stabilizers of G-quadruplex (G4) formation, and their use as therapeutics for the treatment of cancer (e.g., castration-resistant prostate cancer), and other conditions mediated by G4 stabilization.
• US8992991B2
  申请人：——

  公开号：US8992991B2

  公开（公告）日：2015-03-31
• The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists
  作者：Susan Napier、Grant Wishart、William Arbuckle、James Baker、David Barn、Matilda Bingham、Angus Brown、Alan Byford、Chris Claxton、Mark Craighead、Kirsteen Buchanan、Lee Fielding、Lindsay Gibson、Richard Goodwin、Susan Goutcher、Nicholas Irving、Cliona MacSweeney、Rachel Milne、Chris Mort、Jeremy Presland、Hazel Sloan、Fiona Thomson、Zara Turnbull、Trevor Young

  DOI：10.1016/j.bmcl.2011.02.096

  日期：2011.5

  The discovery of a novel series of 8-azabicyclo[3.2.1] octan-3-yl)-3-(4-chlorophenyl) propanamide antagonists of the vasopressin V-1A receptor is disclosed. Compounds 47 and 48 were found to be high affinity, selective vasopressin V-1A antagonists. (C) 2011 Elsevier Ltd. All rights reserved.